Phase II study of antineoplaston A10 and AS2-1 in patients with adenocarcinoma of the prostate
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 29 Sep 2005 New trial record.